GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ASP 3026 | ASP3026
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: ASP-3026 is a second generation ALK inhibitor designed to target ALK rearrangements which are the oncogenic drivers of some non-small cell lung cancers (NSCLCs) and T-cell lymphomas known as ALK- expressing anaplastic large-cell lymphoma (ALK+ALCL) .
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. George SK, Vishwamitra D, Manshouri R, Shi P, Amin HM. (2014)
                                         The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget, 5 (14): 5750-63. [PMID:25026277]  | 
                                                                
| 
                                                                         2. Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T et al.. (2014)
                                         The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther, 13 (2): 329-40. [PMID:24419060]  |